Your session is about to expire
← Back to Search
Monoclonal Antibodies
A Trial of ZL-1201 in Subjects With Advanced Cancer
Phase 1
Waitlist Available
Research Sponsored by Zai Lab (Shanghai) Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 30 days after last dose
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a new drug called ZL-1201 for safety and proper dosage in patients with advanced cancer. It aims to find out if ZL-1201 is safe and how it should be administered.
Eligible Conditions
- Advanced Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from the time of informed consent to 30 days after last dose
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from the time of informed consent to 30 days after last dose
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Safety and tolerability of ZL-1201 when administered as an intravenous (IV) infusion: Incidence of Treatment-Emergent Adverse Events
Secondary study objectives
Immunogenicity
Overall Response Rate (ORR）
Pharmacokinetics: CL
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Single arm, ZL-1201Experimental Treatment1 Intervention
Single arm, ZL-1201
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ZL-1201
2020
Completed Phase 1
~40
Find a Location
Who is running the clinical trial?
Zai Lab (Shanghai) Co., Ltd.Lead Sponsor
28 Previous Clinical Trials
3,617 Total Patients Enrolled
Study PhysicianStudy DirectorZai Laboratory
12 Previous Clinical Trials
3,855 Total Patients Enrolled